The latest results shows that the combination of ivosidenib and enasidenib with standard DA regimen has achieved good efficacy in the treatment of newly diagnosed AML patients with IDH1 or IDH2 mutations. This evidence concerns the gene IDH1 and acute myeloid leukemia.